EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tumor Treating Fields Enhance Temozolomide‐Associated Growth Suppression in Glioblastoma Cells and Patient‐Derived Organoids Through Cell‐Cycle Blockade, Apoptosis, and SMAD ‐Associated Signaling

Haiping Zhu, Yingbo Hou, Xuetao Li, Yi Tang, Zuoyu Jiang iD, Yang Zhang, Xuewen Zhang iD, Jiaming Du iD, Yang Zhu iD, Hanmiao Dong, Yeyang Xu iD, Ruoyu Sun iD und 5 weitere

CNS Neuroscience & Therapeutics · 2026-10 · 32 (10)

DOI: 10.1002/cns.71195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 09.10.2026. Verfasst von Haiping Zhu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Glioblastoma, Temozolomide, Apoptosis, Antineoplastic Agents, Alkylating. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, the National Science and Technology Resource Sharing Service Platform Project, the Suzhou Science and Technology Development Plan Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Glioblastoma (GBM) remains difficult to treat despite multimodal therapy. Tumor Treating Fields (TTF) disrupts mitosis and provides clinical benefit in GBM, but the molecular responses associated with TTF and the effects of combining TTF with temozolomide (TMZ) remain incompletely defined.

Methods

TMZ, TTF, and TMZ + TTF were evaluated in U251 and SHG140 GBM cells and patient‐derived organoids. TTF was applied at 200 kHz and 1.75 V/cm RMS. Viability, colony formation, migration‐related phenotypes, apoptosis, cell‐cycle distribution, Western blotting, qRT‐PCR, RNA‐seq, and organoid morphology/immunofluorescence analyses were performed. SB525334 was used to assess SMAD‐associated signaling.

Results

Combined TMZ + TTF treatment more strongly suppressed cell viability, clonogenic growth, and migration‐related phenotypes than either monotherapy, produced greater disruption of organoid structural integrity, and was accompanied by increased cleaved caspase‐3 activation and apoptotic populations. RNA‐seq identified TTF‐associated transcriptomic changes involving chromatin‐associated processes, DNA replication, and cell‐cycle pathways. TTF was associated with selected SMAD‐related signaling changes, G2/M accumulation, altered checkpoint signaling, and enhanced proapoptotic signaling. SB525334 partially attenuated TTF‐associated SMAD phosphorylation, growth suppression, and cleaved caspase‐3 induction.

Conclusion

TTF enhances TMZ‐associated antitumor responses in GBM cell lines and organoids, accompanied by cell‐cycle blockade, apoptosis‐associated changes, and selected SMAD‐related signaling responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaTemozolomideApoptosisAntineoplastic Agents, AlkylatingBrain NeoplasmsOrganoidsSmad ProteinsCell Cycle CheckpointsHumansSignal TransductionCell Line, TumorCell SurvivalCell Cycle

Stichwörter der Autor:innen

SMAD‐associated signalingglioblastoma (GBM)patient‐derived organoids (PDOs)temozolomide (TMZ)tumor‐ treating fields (TTF)

Substanzen

TemozolomideAntineoplastic Agents, AlkylatingSmad Proteins

Autor:innen und Institutionen

  • Department of Neurosurgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, China.
  • Hunan an Tai Kang Cheng Biotechnology Co. Ltd., Changsha, China.

ORCID-Profile: Zuoyu Jiang, Xuewen Zhang, Jiaming Du, Yang Zhu, Yeyang Xu, Ruoyu Sun, Zijian Han, Lingzhi Xiong, Yulun Huang

Förderung

  • National Natural Science Foundation of China
  • the National Science and Technology Resource Sharing Service Platform Project
  • the Suzhou Science and Technology Development Plan Project
  • the Suzhou Municipal Health Commission Scientific Research Project
  • the Suzhou Medical and Health Innovation Project
  • the Suzhou Industrial Park Healthcare Talent Support Initiative
  • the Gusu Talent Program

Zitieren

APA

Zhu, H., Hou, Y., Li, X., Tang, Y., Jiang, Z., Zhang, Y., Zhang, X., Du, J., Zhu, Y., Dong, H., Xu, Y., Sun, R., Li, C., Han, Z., Lu, J., Xiong, L., & Huang, Y. (2026). Tumor Treating Fields Enhance Temozolomide‐Associated Growth Suppression in Glioblastoma Cells and Patient‐Derived Organoids Through Cell‐Cycle Blockade, Apoptosis, and SMAD ‐Associated Signaling. CNS Neuroscience & Therapeutics, 32(10). https://doi.org/10.1002/cns.71195

Vancouver

Zhu H, Hou Y, Li X, Tang Y, Jiang Z, Zhang Y, et al. Tumor Treating Fields Enhance Temozolomide‐Associated Growth Suppression in Glioblastoma Cells and Patient‐Derived Organoids Through Cell‐Cycle Blockade, Apoptosis, and SMAD ‐Associated Signaling. CNS Neuroscience & Therapeutics. 2026;32(10). doi:10.1002/cns.71195

BibTeX
@article{Zhu2026,
  author = {Zhu, Haiping and Hou, Yingbo and Li, Xuetao and Tang, Yi and Jiang, Zuoyu and Zhang, Yang and Zhang, Xuewen and Du, Jiaming and Zhu, Yang and Dong, Hanmiao and Xu, Yeyang and Sun, Ruoyu and Li, Chenyang and Han, Zijian and Lu, Jian and Xiong, Lingzhi and Huang, Yulun},
  title = {Tumor Treating Fields Enhance Temozolomide‐Associated Growth Suppression in Glioblastoma Cells and Patient‐Derived Organoids Through Cell‐Cycle Blockade, Apoptosis, and SMAD ‐Associated Signaling},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2026},
  volume = {32},
  number = {10},
  doi = {10.1002/cns.71195}
}
Kostenlos starten →